Current Report Filing (8-k)

Date : 09/06/2018 @ 7:33AM
Source : Edgar (US Regulatory)
Stock : Checkpoint Therapeutics, Inc. (CKPT)
Quote : 2.25  0.0 (0.00%) @ 4:00AM
Checkpoint Therapeutics, Inc. share price Chart

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

  

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 6, 2018

 

Checkpoint Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-38128

 

47-2568632

(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

 

2 Gansevoort Street, 9th Floor

New York, New York 10014

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act.
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On September 6, 2018, Checkpoint Therapeutics, Inc. (the “Company”) issued a press release announcing safety and efficacy data from the Company’s Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101. A copy of such press release is being furnished as Exhibit 99.1 .

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished as part of this report:

 

Exhibit
Number

 

Description  

99.1   Press release issued by Checkpoint Therapeutics, Inc., dated September 6, 2018.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CHECKPOINT THERAPEUTICS, INC.  

 

(Registrant)

 

Date: September 6, 2018

 

 
     
By:   /s/ James F. Oliviero  
  Name:    James F. Oliviero  
  Title:    President and Chief Executive Officer  

 

 

 

 

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Historical Stock Chart

1 Year : From Nov 2017 to Nov 2018

Click Here for more Checkpoint Therapeutics, Inc. Charts.

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)
Intraday Stock Chart

Today : Friday 16 November 2018

Click Here for more Checkpoint Therapeutics, Inc. Charts.

Latest CKPT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20181116 09:23:45